Article in Nature Biotechnology about our new name and plans for the future (subscription needed to read full text).
Related stories
LifeArc monetises Keytruda® royalty interests to fund further research and investment
Read more: LifeArc monetises Keytruda® royalty interests to fund further research and investment
First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization Expertise
Read more: First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization ExpertiseImmunotherapy drugs could herald new era in cancer treatment
Read more: Immunotherapy drugs could herald new era in cancer treatment